132 results on '"Torti, Carlo"'
Search Results
2. Depression of lymphocyte activity during cutaneous leishmaniasis: a case report.
- Author
-
Matera, Giovanni, Torti, Carlo, Mazzitelli, Maria, Greco, Giuseppe, Rania, Antonella, Peronace, Cinzia, Settembre, Pio, Galati, Luisa, Giancotti, Aida, Lamberti, Angelo G., Barreca, Giorgio S., Rossi, Marco, Quirino, Angela, Liberto, Maria Carla, and Focà, Alfredo
- Subjects
- *
MENTAL depression , *LYMPHOCYTES , *LEISHMANIASIS , *FLOW cytometry , *B cells - Abstract
Abstract Skin leishmaniasis includes lesions of different appearance, shape, and severity, spanning from alarming diffuse lesions to an asymptomatic course. Moreover, aspecific presentation, as well as challenging differential diagnosis of cutaneous leishmaniasis, may request more in-depth investigations on the intriguing and complex pathogenesis of such infection. A 7-year case of worsening cutaneous leishmaniasis in the left frontoparietal region of the scalp, achieving omolateral eyebrow, in a 68-year-old male patient prompted us to address the immunity profile of peripheral blood lymphocytes. An increase of regulatory CD19+/CD38bright/CD24bright B cell lymphocytes was observed at the front of normal levels of other lymphocytes subpopulations, including CD4+/CD25bright T cells. The total IgG and IgM, as well as proinflammatory subclasses of IgG, were below the normal range. However, IgG4 subclass was found normal. In conclusion, our data may indicate inhibition of humoral immunity associated with an increase of lymphocyte B-regulatory subpopulation. Highlights • A 7-year case of drug-resistant microscopy-verified skin leishmaniasis was studied. • Flow cytometric analysis showed an increase of B-regulatory lymphocytes. • Inhibition of immunity in leishmaniasis may depend on B-regulatory cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort).
- Author
-
Torti, Carlo, Raffetti, Elena, Donato, Francesco, Castelli, Francesco, Maggiolo, Franco, Angarano, Gioacchino, Mazzotta, Francesco, Gori, Andrea, Sighinolfi, Laura, Pan, Angelo, Cauda, Roberto, Scalzini, Alfredo, Quiros-Roldan, Eugenia, Nasta, Paola, Gregis, Giampietro, Benatti, Simone, Digiambenedetto, Simona, Ladisa, Nicoletta, Giralda, Mariarosaria, and Saracino, Annalisa
- Subjects
- *
HIGHLY active antiretroviral therapy , *THERAPEUTICS , *HIV infections , *MEDICAL care of HIV-positive persons , *ANTIRETROVIRAL agents , *AIDS - Published
- 2017
- Full Text
- View/download PDF
4. Professional Acquisition of M. bovis in Calabria Region (Southern Italy): A Challenging Case of Osteomyelitis in a Migrant Patient from Bulgaria.
- Author
-
Quirino, Angela, Torti, Carlo, Strazzulla, Alessio, Nisticò, Salvatore, Galati, Luisa, Barreca, Giorgio Settimo, Lamberti, Angelo Giuseppe, Berardelli, Giuseppina, Pacciarini, Maria, Gasparini, Giorgio, Pisani, Vincenzo, Gambardella, Antonio, Liberto, Maria Carla, and Focà, Alfredo
- Subjects
- *
OSTEOMYELITIS , *MYCOBACTERIUM bovis , *ENTEROBACTER , *MIXED infections - Abstract
We report herein the first case of a coinfection with Brucella spp., M. bovis, and Enterobacter cloacae in a butcher who moved from Bulgaria to Italy. Molecular typing suggested professional acquisition of M. bovis in Italy. So, surveillance and preventive measures need to be implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Update on different aspects of HCV variability: focus on NS5B polymerase.
- Author
-
Marascio, Nadia, Torti, Carlo, Liberto, Maria Carla, and Focà, Alfredo
- Abstract
The study of hepatitis C virus (HCV) genotypes/subtypes, quasispecies and recombinants obtained by virus genome sequencing are important for epidemiological studies, to trace the source of infection, for development of new direct acting antivirals (DAAs) therapy and for understanding antiviral selection pressures. The HCV NS5B gene encodes a polymerase, which is responsible for virus replication and is a potential target for the development of antiviral agents. Many studies for classification of HCV use a particular segment of the NS5B gene, in addition to other specific regions, and phylogenetic analysis. Actually, some nucleoside/nucleotide analogues and nonnucleoside inhibitors target NS5B protein. This review focuses on HCV variability, phylogenetic analysis and the role of NS5B in the virus-host interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Emergence of Exhausted B Cells in Asymptomatic HIV-1-Infected Patients Naïve for HAART is Related to Reduced Immune Surveillance.
- Author
-
Fogli, Manuela, Torti, Carlo, Malacarne, Fabio, Fiorentini, Simona, Albani, Melania, Izzo, Ilaria, Giagulli, Cinzia, Maggi, Fabrizio, Carosi, Giampiero, and Caruso, Arnaldo
- Subjects
- *
HIV-positive persons , *HIGHLY active antiretroviral therapy , *B cells , *CD4 antigen , *T cells - Abstract
Alterations of B cell subpopulations have been described up to date as characterizing advanced stage of HIV-1 infection. However, whether such defects are relevant in subjects with a preserved number of CD4+ T cells (>350 cells/μL) is unclear. In a crosssectional study, we investigated if signs of B cells exhaustion and impaired viral immune surveillance are present in a cohort of 43 asymptomatic HIV-1-infected patients with preserved CD4+ T cell counts (>350 cells/μL) and highly active antiretroviral therapy (HAART) untreated. A dramatic expansion of exhausted tissue-like memory B cells (CD10-CD21lowCD27-) was observed. B cells alteration was related to an increase in Torque teno virus (TTV) load, used as surrogate marker of immune function. Successfully HAART-treated patients showed normalization of B cell subpopulations frequency and TTV load. These results provide new insights on B cell in HIV-1 infection and show that development of B cell abnormalities precedes CD4+ T cell decline. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
- Author
-
Torti, Carlo, d'Arminio-Monforte, Antonella, Pozniak, Anton L., Lapadula, Giuseppe, Cologni, Giuliana, Antinori, Andrea, De Luca, Andrea, Mussini, Cristina, Castagna, Antonella, Cicconi, Paola, Minoli, Lorenzo, Costantini, Andrea, Carosi, Giampiero, Hua Liang, and Cesana, Bruno M.
- Subjects
- *
FLOW cytometry , *HIV , *NUCLEOSIDES , *PROTEASE inhibitors , *REGRESSION analysis - Abstract
Background: Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce. Methods: Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after the switch, and last visit). Finally, we explored whether the CD4+ counts evolved differently in patients who switched to NNRTI or NRTI-only regimens by considering: the overall CD4+ trends, the time to CD4+≥ 500/mm³ after the switch, and the area-under-the-curve (AUC) of the CD4+ after the switch. Results: Eight hundred and ninety-six patients, followed for a median of 2,121 days, were included. At TPLR, hinges occurred in 581/844 (68.9%), but in only 40/581 (6.9%) within a time interval (180 days) compatible with a possible relationship to the switch; furthermore, in 19/40 cases, CD4+ counts appeared to decrease after the hinges. In comparison with the NNRTI group, the NRTI group showed CD4+ count greater at baseline (P = 0.0234) and before the switch (P ≤ 0.0001), superior CD4+ T-cell increases after HAART was started, lower probability of not achieving CD4+ ≥ 500/mm³ (P = 0.0024), and, finally, no significant differences in the CD4+ T-cell AUC after the switch after adjusting for possible confounders (propensity score and pre-switch AUC). Persistence at CD4+ < 200/ mm³ was observed in 34/435 (7.5%) patients, and a decrease below this level was found in only 10/259 (3.9%) with baseline CD4+ ≥ 350/mm³. Conclusions: Switching from first-line PI to NNRTI- or NRTI-based regimens did not seem to impair CD4+ trend over long-term follow-up. Although the greater CD4+ increases in patients who switched to the NRTI-only regimen was due to higher CD4+ counts before the switch, several statistical analyses consistently showed that switching to this regimen did not damage the ongoing immune-reconstitution. Lastly, the observation that CD4+ T-cell counts remained low or decreased in the long term despite virological success merits further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
8. Screening and Management of HIV-2-Infected Individuals in Northern Italy.
- Author
-
Costarelli, Silvia, Torti, Carlo, Rodella, Anna, Baldanti, Fausto, Paolucci, Stefania, Lapadula, Giuseppe, Manca, Nino, Quiros-Roldan, Eugenia, Izzo, Ilaria, and Carosi, Giampiero
- Subjects
- *
HIV infections , *HIV-positive persons , *HIV , *AFRICANS , *DISEASE management , *DISEASES - Abstract
There is a lack of updated estimates of HIV-2 infection in Italy. Moreover, lack of standardized HIV-2 viral load (VL) and drug resistance tests challenges clinical practice. Among 2941 HIV-positive patients followed in our center (Brescia, Northern Italy), 220 (7.5%) were African at the beginning of the study period. We assessed a population of 151 HIV-Ab positive patients (141 of African origin), presenting for routine blood testing from January 2006 to May 2007. Those found infected with HIV-2 started an appropriate disease management with HIV-2 VL and genotypic drug resistance testing. Sixteen of 151 (10.6%) patients were positive for HIV-2. Of those 16 patients, 14 came from Africa. Among 7 experienced patients, 1 was responding to nelfinavir and 4 to lopinavir/ritonavir-containing regimens. Two patients were failing treatment: 1 patient was switched to a saquinavir/ritonavir-containing regimen and responded. The remaining patient switched to lamivudine+atazanavir+saquinavir+ritonavir did not respond, having had previous experience to multiple ineffective drugs, resulting in a very complex HIV-2 drug-resistance pattern. Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
9. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
- Author
-
Torti, Carlo, Costarelli, Silvia, De Silvestri, Annalisa, Quiros-Roldan, Eugenia, Lapadula, Giuseppe, Cologni, Giuliana, Paraninfo, Giuseppe, Castelnuovo, Filippo, Puoti, Massimo, Carosi, Giampiero, and BHCC Study Group
- Subjects
- *
LIVER failure , *AMINOTRANSFERASES , *ANTIRETROVIRAL agents , *HIV-positive persons , *HEPATITIS C , *T-cell receptor genes , *REGRESSION analysis , *HEPATOTOXICOLOGY , *MEDICAL research , *HIV infection complications , *ASPARTATE aminotransferase , *COMBINATION drug therapy , *HEPATITIS viruses , *HIV , *HIV infections , *LIVER , *LIVER function tests , *LONGITUDINAL method , *SEX distribution , *VIRAL antibodies , *ALANINE aminotransferase , *RETROSPECTIVE studies , *NEVIRAPINE , *ANTI-HIV agents , *CD4 lymphocyte count , *REVERSE transcriptase inhibitors , *DISEASE complications , *THERAPEUTICS - Abstract
Background: Nevirapine-containing regimens have been associated with a risk of significant elevations of liver transaminase levels. Higher risk in antiretroviral-naive populations has been related to gender and CD4+ T-cell count (women with CD4+ T-cell counts of > or =250/mm(3) or men with CD4+ T-cell counts of > or =400/mm(3), i.e. group at risk). However, recent studies do not confirm this association in HIV populations comprising patients who are antiretroviral-experienced. Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV).Methods: Analysis of HIV-positive patients receiving nevirapine-containing regimens for the first time was conducted. Grade > or =III hepatotoxicity (i.e. > or =5 x upper limit of normal in alanine aminotranferase or aspartate aminotransferase levels) was the primary endpoint. Univariate and multivariable Cox proportional hazard regression models were separately conducted among HCV-antibody (Ab)-positive and HCV-Ab-negative patients.Results: Amongst 905 patients, 49% were HCV-Ab-positive and 79% were antiretroviral-experienced. Grade > or =III liver transaminase elevations developed in 7.1% of patients, accounting for an incidence of 2.47 (95% CI 1.97, 3.09) per 100 patient-years of follow-up. HCV-Ab reactivity was associated with a 3-fold increase in risk of developing relevant liver transaminase elevations (95% CI 1.75, 5.3; p < 0.001), whereas gender and CD4+ T-cell count did not impact significantly. When analysis was performed in HCV-Ab-negative patients, the outcome was independently correlated with the group at risk (hazard ratio [HR] 3.66; 95% CI 1.20, 11.14; p = 0.022). By contrast, in HCV-Ab-positive patients, the group at risk was not significantly associated with the outcome.Conclusions: Most of the excess rates of relevant raised transaminase levels in patients prescribed nevirapine-containing regimens could be attributed to HCV co-infection. Gender and CD4+ T-cell count appeared to have a statistically significant impact on the risk of relevant transaminase level elevations in HCV-negative, but not in HCV-positive patients, probably due to a diluting effect of HCV. Incidence of hepatic events after nevirapine-containing regimens did not appear to be a major concern in our cohort of patients who were mainly antiretroviral-experienced and negative for HCV-Ab. Preferably, nevirapine should be avoided in HCV co-infected patients and in males with CD4+ T-cell counts of > or =400/mm(3) or females with CD4+ T-cell counts of > or =250/mm(3). [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
10. Adherence And Plasma Drug Concentrations Are Predictors of Confirmed Virologic Response after 24-Week Salvage Highly Active Antiretroviral Therapy.
- Author
-
Quiros-Roldan, Eugenia, Torti, Carlo, Lapadula, Giuseppe, Ladisa, Nicoletta, Micheli, Valeria, Patroni, Andrea, Cusato, Maria, Pierotti, Piera, Tirelli, Valeria, Uccelli, Maria Cristina, Di Giambenedetto, Simona, Castelnuovo, Filippo, Gargiulo, Franco, Manca, Nino, and Carosi, Giampiero
- Subjects
- *
ANTIVIRAL agents , *THERAPEUTICS , *REGRESSION analysis , *HIV , *PROTEASE inhibitors - Abstract
Data from 197 patients for whom highly active antiretroviral therapy (HAART) failed, who started a new regimen chosen under the guide of resistance testing results interpreted by experts, were retrospectively studied, provided that at least 2 determinations of adherence and plasma drug concentrations were performed during the follow-up. Univariate and multivariable logistic regression analyses were conducted, using confirmed virologic response at week 24 as outcome measure (i.e., achievement of undetectable HIV plasma viral load at any time point before week 24 and its maintenance up to week 24). Suboptimal drug concentrations (odds ratio [OR]: 0.3; 95% confidence interval [CI] 0.2–0.7; p = 0.006) and suboptimal adherence (OR: 0.4; 95% CI 0.2–0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1–5.3; p = 0.032). [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients
- Author
-
Torti, Carlo, Lapadula, Giuseppe, Uccelli, Maria Cristina, Quiros-Roldan, Eugenia, Regazzi, Mario, Ladisa, Nicoletta, Micheli, Valeria, Orani, Anna, Patroni, Andrea, Caputo, Sergio Lo, Tirelli, Valeria, Di Giambenedetto, Simona, Cologni, Giuliana, Costarelli, Silvia, Gargiulo, Franco, Manca, Nino, and Carosi, Giampiero
- Subjects
- *
VIRAL hepatitis , *ANTIRETROVIRAL agents , *HIV-positive persons , *HIV , *HEPATITIS B virus , *AMINOTRANSFERASES - Abstract
Abstract: It is still controversial whether viral hepatitis co-infection can influence antiretroviral plasma drug concentrations and whether drug concentrations are correlated with liver enzyme elevations during highly active antiretroviral therapy. An analysis of data from a cohort of 220 human immunodeficiency virus (HIV)-infected patients was conducted. Univariate and multivariate logistic analyses were performed to identify predictors of plasma drug concentrations. The association of transaminase elevation with higher plasma drug concentrations was explored following stratification of patients into HIV monoinfected and hepatitis C virus (HCV) and/or hepatitis B virus (HBV) co-infected groups. Hepatitis co-infections were independently correlated with drug concentrations above the therapeutic cut-offs at Week 1 (P = 0.06), Week 4 (P = 0.04) and Week 12 (P = 0.005). The apparent effect was independent of the possible impact exerted by other variables such as demographics and medication adherence. The incidence of relevant hypertransaminasaemia was low. Patients with hepatitis co-infections had higher rates of transaminase elevation than monoinfected HIV patients; however, risk of transaminase elevation was not associated with drug concentrations. The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
12. Influence of Folate Serum Concentration on Plasma Homocysteine Levels in HIV-Positive Patients Exposed to Protease Inhibitors Undergoing HAART.
- Author
-
Uccelli, Maria Cristina, Torti, Carlo, Giuseppe, Lapadula, Labate, Lorena, Cologni, Giuliana, Tirelli, Valeria, Moretti, Francesca, Costarelli, Silvia, Quiros-Roldan, Eugenia, and Carosi, Giampiero
- Subjects
- *
HIV-positive persons , *PATIENTS , *ANTIRETROVIRAL agents , *VITAMIN B12 , *FOLIC acid - Abstract
Background: Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet. Methods: HIV-positive patients on stable highly active antiretroviral therapy (HAART) regimens for at least 6 months were enrolled in this cross-sectional study. Among other factors, vitamin B12, folate and length of exposure to protease inhibitors (PIs) were evaluated for their possible correlation with hyper-Hcy (>13 μmol/l in females; >15 μmol/l in males) by logistic regression analysis. Results: Ninety-eight HIV-positive patients were recruited. Twenty-eight (28.6%) had hyper-Hcy. Length of exposure to antiretroviral therapy and PIs did not result to be significantly associated with hyper-Hcy risk. Normal folate level was the only factor associated with the outcome, resulting protective from hyper-Hcy, either at univariate (OR = 0.22; CI 95% = 0.06–0.86; p = 0.029) and multivariable (OR = 0.24; CI 95% = 0.06–0.94; p = 0.04) logistic regression analysis. Folate predictive value of hyper-Hcy risk was driven by levels in the lowest quartiles of the study population (i.e. <10.9 nmol/l). Conclusions: No significant correlations were observed between hyper-Hcy and length of exposure to antiretroviral therapy or PIs. Folate could be a confounding factor in the association between hyper-Hcy and PI exposure found by others. The potential value of folate supplementation, in those who are deficient and in those with hyper-Hcy, merits study. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
13. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors
- Author
-
Torti, Carlo, Uccelli, Maria Cristina, Quiros-Roldan, Eugenia, Gargiulo, Franco, Tirelli, Valeria, Lapadula, Giuseppe, Regazzi, Mario, Pierotti, Piera, Tinelli, Carmine, Luca, Andrea De, Patroni, Andrea, Manca, Nino, and Carosi, Giampiero
- Subjects
- *
HIGHLY active antiretroviral therapy , *ANTIRETROVIRAL agents , *PROTEASE inhibitors , *DRUG resistance , *HIV - Abstract
Abstract: Objective: To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure. Design: Retrospective analysis of a prospective trial. Methods: Lopinavir GIQ was calculated as the ratio between the mean trough concentration (C trough) and the number of protease mutations using eight different HIV drug resistance mutation lists or algorithms. Early (by week 12) and confirmed (up to week 24) virological response (HIV-RNA<400copies/mL, ECVR) was used as dependent variable in logistic regression model. Results: Seventy-one of 109 (65%) patients achieved ECVR. At multivariable logistic regression analysis, each μg/mL increase of GIQ was correlated with increasing probability of ECVR as far as the following mutations were computed: multi-protease inhibitor (PI) associated mutations listed by IAS (OR=1.17; 95% CI=0.99–1.39; P =0.058), mutations associated with LPV resistance by ANRS algorithm (OR=1.21; 95% CI=1.02–1.44; P =0.03), major mutations associated with LPV resistance by Stanford database (OR=1.16; 95% CI=1–1.35; P =0.05), and the whole set of mutations associated with LPV resistance in the same database (OR=1.22; 95% CI=1.02–1.46; P =0.03). Using ROC curve method, a specific threshold GIQ was assessed, above which this parameter could predict ECVR with the highest sensitivity (74.6% with GIQ obtained through Stanford LPV mutations) or specificity (89.5% with GIQ obtained through ANRS LPV mutations). Conclusions: Our results suggest that increasing GIQ can improve virological outcome even in patients with limited exposure to PIs. Further studies are necessary to understand what HIV protease mutations should be considered and whether such mutations should be weighted differently to improve LPV GIQ predictive value. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
14. Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1 -Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen Results From the EPOKA-MASTER Cohort.
- Author
-
Torti, Carlo, Lapadula, Giuseppe, Puoti, Massimo, Casari, Salvatore, Uccelli, Maria Cristina, Cristini, Graziella, Bella, Daniele, Pastore, Giuseppe, Ladisa, Nicoletta, Minoli, Lorenzo, Sotgiu, Giovanni, Lo Caputo, Sergio, Bonora, Stefano, and Carosi, Giampiero
- Subjects
- *
HEPATITIS C virus , *ANTIVIRAL agents , *EFFECT of drugs on enzymes , *HEPATOTOXICOLOGY , *HIV-positive persons , *HIV virus enzymes , *IMMUNE response - Abstract
The article evaluates the impact of Hepatitis C virus-3 (HCV-3) on the elevation of liver enzymes in HIV-1 positive individual after the administration of highly active antiretroviral regimen therapy (HAART). Patients with HCV-3 had higher CD4 T Cell count at nadir and higher transaminase levels at baseline. The study showed the relationship between higher CD4 T cell count at baseline with a lower risk of hepatotoxicity. It suggest that HCV-3 influence specific immune response restored by HAART and determines hepatotoxicity.
- Published
- 2006
- Full Text
- View/download PDF
15. A Randomized Controlled Trial to Evaluate Antiretroviral Salvage Therapy Guided by Rules-Based or Phenotype-Driven HIV-1 Genotypic Drug-Resistance Interpretation With or Without Concentration-Controlled Intervention: The Resistance and Dosage Adapted...
- Author
-
Torti, Carlo, Quiros-roldan, Euqenia, Reqazzi, Mario, De Luca, Andrea, Mazzotta, Francesco, Antinori, Andrea, Ladisa, Nicoletta, Micheli, Valeria, Orani, Anna, Patroni, Andrea, Villani, Paola, Lo Caputo, Serqio, Moretti, Francesca, Giambenedetto, Simona Di, Castelnuovo, Filippo, Maggi, Paolo, Tinelli, Carmine, and Carosi, Giampiero
- Subjects
- *
ANTIRETROVIRAL agents , *THERAPEUTICS , *PROTEASE inhibitors , *FELINE immunodeficiency virus , *DRUG dosage , *ENZYME inhibitors - Abstract
Background. It is not well defined whether concentration-controlled intervention (CCI) and rules-based human immunodeficiency virus (HIV) type 1 genotype drug-resistance interpretation (GI) or virtual phenotype drug-resistance interpretation (VPI) may improve the outcome of HIV salvage therapy. Methods. In a prospective, randomized, controlled trial, patients were randomized (on a factorial basis) to change treatment after either GI or VPI, and they then were further randomized to the control arm (no CCI) or the CCI arm. Protease inhibitor (P1) and nonnucleoside reverse-transcriptase inhibitor (NNRTI) trough concen- tration (Ctrough) values were determined at weeks 1, 4, 12, and 24 of the study. Results. Among 230 patients, virological benefit (defined by an HIV RNA load of <400 copies/mL at week 24) was not statistically different, either between patients in the GI and VPI arms or between patients in the CCI and control arms. A virological benefit was found for patients in the CCI arm, compared with patients in the control arm, but this benefit was not statistically significant (56.8% vs. 64.3% at week 4 and 63.6% vs. 74% at week 12). Dosage adaptation was possible for only a fraction of patients, because of low rates of treatment adherence or patient refusal to increase dosages. In the logistic regression analysis, independent predictors of virological response at week 24 were a P1 Ctrough value and/or an NNRTI Ctrouth value in the higher quartiles (or above cutoff levels) and a low number of PIs previously received. Moreover, receipt of a regimen that contained PIs boosted with ritonavir was an independent predictor of virological response. Conclusions. The present study did not support the routine use of CCI for patients undergoing salvage treatment, probably as a result of existing difficulties associated with its clinical application. However, a higher Ctrough value appeared to be correlated with treatment response. No major differences were found between VPI or GI when they are used together with expert advice for the selection of salvage treatment combinations. [ABSTRACT FROM AUTHOR]
- Published
- 2005
16. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
- Author
-
Torti, Carlo, Lapadula, Giuseppe, Casari, Salvatore, Puoti, Massimo, Nelson, Mark, Quiros-Roldan, Eugenia, Bella, Daniele, Pastore, Giuseppe, Ladisa, Nicoletta, Minoli, Lorenzo, Sotgiu, Giovanni, Mazzotta, Francesco, Lo Caputo, Sergio, Di Perri, Giovanni, Filice, Gaetano, Tinelli, Carmine, and Carosi, Giampiero
- Subjects
- *
ANTIRETROVIRAL agents , *HIGHLY active antiretroviral therapy , *LIVER , *ENZYMES , *THERAPEUTIC use of protease inhibitors , *HEPATOTOXICOLOGY - Abstract
Background: The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully assessed. Methods: Retrospective analysis of a prospective cohort of 1,038 HIV-HCV co-infected patients who commenced a new HAART in the Italian MASTER database. Patients were stratified into naïve and experienced to antiretroviral therapy before starting the study regimens. Time to grade ≥III hepatotoxicity (as by ACTG classification) was the primary outcome. Secondary outcome was time to grade IV hepatotoxicity. Results: Incidence of grade ≥III hepatotoxicity was 17.71 per 100 patient-years (p-yr) of follow up in naïve patient group and 8.22 per 100 p-yrs in experienced group (grade IV: 4.13 per 100 p-yrs and 1.08 per 100 p-yrs, respectively). In the latter group, the only independent factors associated with shorter time to the event at proportional hazards regression model were: previous liver transaminase elevations to grade ≥III, higher baseline alanine amino-transferase values, and use of a non nucleoside reverse transcriptase inhibitor based regimen. In the naive group, baseline aspartate transaminase level was associated with the primary outcome. Conclusion: Use of a single or multiple protease inhibitor based regimen was not associated with risk of hepatotoxicity in either naïve or experienced patient groups to a statistically significant extent. A cautious approach with strict monitoring should be applied in HIV-HCV co-infected experienced patients with previous liver transaminase elevations, higher baseline alanine aminotransferase values and who receive regimens containing non nucleoside reverse transcriptase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
17. Comparison between Rules-Based Human Immunodeficiency Virus Type 1 Genotype Interpretations and Real or Virtual Phenotype: Concordance Analysis and Correlation with Clinical Outcome in Heavily Treated Patients.
- Author
-
Torti, Carlo, Quiros-Roldan, Eugenia, Keulen, Wilco, Scudeller, Luigia, Caputo, Sergio Lo, Boucher, Charles, Castelli, Francesco, Mazzotta, Francesco, Pierotti, Piera, Been-Tiktak, Anne Mieke, Buccoliero, Giovanni, De Gennaro, Michele, Carosi, Giampiero, and Tinelli, Carmine
- Subjects
- *
HIV infections , *PHENOTYPES , *HIV , *RNA - Abstract
We compared 2 rules-based genotype interpretation systems and real or virtual phenotype through a retrospective analysis of a prospective trial. Genotypes were determined with VircoGEN II (VIRCO) and were interpreted with either RetroGram 1.4 or TRUGENE HIV-1 (guidelines 3.0) or original virtual phenotype (Virtual Phenotype; VIRCO), as available in the year 2000. Among 188 human immunodeficiency virus (HIV) type 1 isolates, overall concordance (κ agreement) was observed for the 2 rules-based systems, whereas striking discordances were noted between them and real and virtual phenotype interpretations for stavudine, dida-nosine, zalcitabine, abacavir, and amprenavir (κ<0.4). Clinical evaluation of a subset of 173 patients showed that both rules-based sensitivity scores were independently associated with HIV RNA loads <400 copies/mL at week 16 of during-treatment analysis (TRUGENE: odds ratio [OR], 2.90; 95% confidence interval [CI], 1.52-5.52;P =.001; RetroGram: OR, 2.34; 95% CI, 1.21-4.55;P =.012), whereas, in contrast to real or virtual phenotype, interpretations according to biological cut-offs were not (OR, 1.91; 95% CI, 0.77-4.76;P =.162). [ABSTRACT FROM AUTHOR]
- Published
- 2003
18. Severe Hepatotoxicity During Combination Antiretroviral Treatment: Incidence, Liver Histology, and Outcome.
- Author
-
Puoti, Massimo, Torti, Carlo, Ripamonti, Diego, Castelli, Francesco, Zaltron, Serena, Zanini, Barbara, Spinetti, Angiola, Putzolu, Valeria, Casari, Salvatore, Tomasoni, Lina, Quiros-Roldan, Eugenia, Favret, Maurizio, Berchich, Luisa, Grigolato, Piergiovanni, Callea, Francesco, and Carosi, Giampiero
- Subjects
- *
HEPATOTOXICOLOGY , *ANTIVIRAL agents , *LIVER failure , *HEPATITIS C - Abstract
Assesses incidence, risk factors, histology and outcome of severe hepatotoxicity (SH) during antiretroviral treatment. Liver function tests; Estimates of SH and liver failure in a large population-based setting where hepatitis C virus coinfection is highly prevalent; Effectiveness of antihepatitis pre- or co-medication.
- Published
- 2003
- Full Text
- View/download PDF
19. Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, State of Paranà, Brasil: implications for control.
- Author
-
Scolari, Carla, Torti, Carlo, Beltrame, Anna, Matteelli, Alberto, Castelli, Francesco, Gulletta, Maurizio, Ribas, Milton, Morana, Serenella, Urbani, Carlo, Scolari, C, Torti, C, Beltrame, A, Matteelli, A, Castelli, F, Gulletta, M, Ribas, M, Morana, S, and Urbani, C
- Subjects
- *
HELMINTHIASIS in children , *JUVENILE diseases - Abstract
Soil-transmitted helminth (STH) infections represent a major public health problem in poor and developing countries. During the period September-October 1998 we conducted an epidemiological survey of STH infections in schoolchildren of an urban area (group A) and an indigenous reserve (group B), in the Municipality of Ortigueira, State of Paranà, Brazil, to assess potential benefits of mass treatment. Stool samples were examined for helminth eggs by quantitative (Kato-Katz) technique to determine the prevalence and intensity of intestinal parasitic infection. Moreover, we examined the relationship between prevalence and intensity of STH infections and housing/hygienic factors (by means of a 7-item questionnaire). 236 schoolchildren aged 5-15 years were enrolled, 136 in group A and 100 in group B. The prevalence of STH infections was significantly higher in group B (93%) than in group A (22%) (P < 0.001). Detected parasites were: A. lumbricoides (16.1% prevalence in group A, 88% in group B, P < 0.001), hookworms (5.8% in group A, 52% in group B, P < 0.001) and T. trichiura (5.1% in group A, 2% in group B, P = 0.2). Heavy infections were detected in 2.9% and 23% of the children in group A and B, respectively (P < 0.001). Housing/hygienic indicators were significantly poorer in group B. A statistically significant correlation was observed between total prevalence of STH infections and prevalence of high-intensity infections with most housing/hygienic variables. On the basis of these results, mass treatment and educational interventions were suggested for the indigenous community, whereas target treatment and educational interventions were suggested for the urban community. Even in a geographically homogeneous area different epidemiological realities can be found, which in turn can influence infection levels and control programmes. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
20. Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study.
- Author
-
Rotundo, Salvatore, Berardelli, Lavinia, Gullì, Sara, La Gamba, Valentina, Lionello, Rosaria, Russo, Alessandro, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
COVID-19 , *IMMUNOCOMPROMISED patients , *COHORT analysis , *VIRAL shedding , *RETROSPECTIVE studies - Abstract
This single-centre retrospective cohort study reports on the results of a descriptive (non-comparative) retrospective cohort study of early initiation of antivirals and combined monoclonal antibody therapy (mAbs) in 48 severely immunocompromised patients with COVID-19. The study assessed the outcomes and the duration of viral shedding. The patients started early combined therapy (ECT) a median of 2 days (interquartile range [IQR]: 1–3 days) after the diagnosis of SARS-CoV-2 infection. Except for 1 patient who died due COVID-19-related respiratory failure, patients had their first negative nasopharyngeal swab result after a median of 11 days (IQR: 6–17 days) after starting combined therapy. There were no reports of severe side effects. During a follow-up period of 512 days (interquartile range [IQR]: 413–575 days), 6 patients (12.5%) died and 16 (33.3%) were admitted to hospital. Moreover, 12 patients (25%) were diagnosed with SARS-CoV-2 reinfection a median of 245 days (IQR: 138–401 days) after starting combined treatment. No relapses were reported. Although there was no comparison group, these results compare favourably with the outcomes of severely immunocompromised patients with COVID-19 reported in the literature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. A king in the CASTLE? Optimum initial HIV protease inhibitor.
- Author
-
Torti, Carlo and Frank, Ian
- Subjects
- *
ANTIRETROVIRAL agents , *HIV infections , *PROTEASE inhibitors , *CLINICAL medicine research , *HIV-positive persons , *AIDS - Abstract
The article discusses a study, published elsewhere in the same issue, titled "Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48-week efficacy and safety results of the CASTLE study." Potential improvements in the antiretroviral treatment of HIV are the focus of the study. It is said that a variety of protease inhibitors may be used with equal efficacy, and it is reasonable to choose among them using considerations such as toxicity and patients' perception of tolerability.
- Published
- 2008
- Full Text
- View/download PDF
22. Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series.
- Author
-
Torti, Carlo, Mazzitelli, Maria, Longhini, Federico, Garofalo, Eugenio, Bruni, Andrea, Giancotti, Aida, Barreca, Giorgio Settimo, Quirino, Angela, Liberto, Maria Carla, Serapide, Francesca, Matera, Giovanni, Trecarichi, Enrico Maria, Navalesi, Paolo, the IMAGES (Integrated MAnaGEment of Sepsis) Group, Pisani, Vincenzo, Costa, Chiara, Greco, Giuseppe, Scaglione, Vincenzo, Lionello, Rosaria, and La Gamba, Valentina
- Subjects
- *
INFLUENZA , *ADULT respiratory distress syndrome , *EXTRACORPOREAL membrane oxygenation , *BACTERIAL diseases , *INTENSIVE care units , *POLYMERASE chain reaction - Abstract
Background: Intravenous (IV) zanamivir could be a suitable alternative for the treatment of severe influenza A(H1N1)pdm09 infection in patients who are unable to take oral or inhaled medication, for example, those on mechanical ventilation and extracorporeal membrane oxygenation (ECMO). However, data on the clinical outcomes of such patients is limited.Case Presentation: We report the clinical outcomes of four patients who were admitted at the intensive care unit during the 2017-2018 influenza season with severe sepsis (SOFA score > 11) and acute respiratory distress syndrome requiring ECMO and mechanical ventilation. Two patients were immune-compromised. The A(H1N1)pdm09 genome was confirmed by polymerase chain reaction (PCR) on nasopharyngeal specimen swabs prior to administration of IV zanamivir at a dose of 600 mg twice daily. Weekly qualitative PCR analysis was done to monitor viral clearance, with zanamivir treatment being discontinued upon receipt of negative results. In addition, the patients were managed for concomitant multidrug-resistant bacterial infections, with infection resolution confirmed with blood cultures. The median time for zanamivir treatment was 10 days (IQR 10-17). The clinical outcome was favourable with all four patients surviving and improving clinically. All four patients achieved viral clearance of A(H1N1)pdm09 genome, and resolution of multidrug-resistant bacterial infections.Conclusions: IV zanamivir could be a good therapeutic option in patients with severe influenza A(H1N1)pdm09 infection who are unable to take oral or aerosolised antiviral medication. We recommend prospective randomized control trials to support this hypothesis. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
23. The Omicron XBB.1 Variant and Its Descendants: Genomic Mutations, Rapid Dissemination and Notable Characteristics.
- Author
-
Giancotti, Raffaele, Lomoio, Ugo, Puccio, Barbara, Tradigo, Giuseppe, Vizza, Patrizia, Torti, Carlo, Veltri, Pierangelo, and Guzzi, Pietro Hiram
- Subjects
- *
SARS-CoV-2 Omicron variant , *SARS-CoV-2 , *VIRAL proteins , *PROTEIN structure , *ANGIOTENSIN converting enzyme - Abstract
Simple Summary: SARS-CoV-2 XBB variant was isolated in Singapore in 2022. Sequence changes and their relation with spike protein structure is studied with respect to XBB subvariants. Structural and functional distinctions of the variants is also reported. Affonity binding between the spike protein and ACE2 is reported. The relation among sequence and structure has been studied. The SARS-CoV-2 virus, which is a major threat to human health, has undergone many mutations during the replication process due to errors in the replication steps and modifications in the structure of viral proteins. The XBB variant was identified for the first time in Singapore in the fall of 2022. It was then detected in other countries, including the United States, Canada, and the United Kingdom. We study the impact of sequence changes on spike protein structure on the subvariants of XBB, with particular attention to the velocity of variant diffusion and virus activity with respect to its diffusion. We examine the structural and functional distinctions of the variants in three different conformations: (i) spike glycoprotein in complex with ACE2 (1-up state), (ii) spike glycoprotein (closed-1 state), and (iii) S protein (open-1 state). We also estimate the affinity binding between the spike protein and ACE2. The market binding affinity observed in specific variants raises questions about the efficacy of current vaccines in preparing the immune system for virus variant recognition. This work may be useful in devising strategies to manage the ongoing COVID-19 pandemic. To stay ahead of the virus evolution, further research and surveillance should be carried out to adjust public health measures accordingly. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients.
- Author
-
Mazzitelli, Maria, Torti, Carlo, Sabatino, Jolanda, D'Ascoli, Greta Luana, Costa, Chiara, Pisani, Vincenzo, Raffetti, Elena, De Rosa, Salvatore, Strazzulla, Alessio, Focà, Alfredo, Liberto, Maria Carla, Indolfi, Ciro, and CARDIAC study group
- Subjects
- *
HEPATITIS C virus , *CARDIOVASCULAR diseases risk factors , *CARDIOTOXICITY , *BODY mass index ,SOFOSBUVIR - Abstract
Background: Possible cardiotoxicity of sofosbuvir in humans has not been demonstrated yet. Also, since HCV can exert deleterious effects on hearth function, it is of interest to know whether HCV eradication provides any benefits using global longitudinal strain (GLS), a measure of left ventricular function more reliable than ejection fraction (EF).Methods: Patients eligible for treatment with the combination therapy for HCV were invited to perform a transthoracic cardiac ultrasound at four different time points: before starting treatment, after one month, at the end of treatment and, after six month. Left ventricular function was measured with both EF and GLS.Results: From March 2015 to December 2016, 82 patients were enrolled. Fifty-six percent patients were males. Mean age was 66.12 (SD: 9.25) years. About 20% patients did not present any cardiovascular risk factors or comorbidities. A worsening trend of GLS was observed. Variations were not found to be statistically significant when EF was studied along the follow-up. However, when GLS was studied, its variations were found to be statistically significant indicating a worsening effect, albeit with different trends in patients who underwent treatment for three months compared to six months. Worsening of GLS was found to be statistically significant even after adjusting for body mass index and liver fibrosis, independently from treatment duration.Conclusions: Our results showed unexpected worsening of left ventricular function when measured through GLS after HCV treatment response induced by DAAs including sofosbuvir. Although this result is not proven to be clinically significant, the safety profile of sofosbuvir-based regimens needs to be studied further. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. The spike-specific TCRβ repertoire shows distinct features in unvaccinated or vaccinated patients with SARS-CoV-2 infection.
- Author
-
Vecchio, Eleonora, Rotundo, Salvatore, Veneziano, Claudia, Abatino, Antonio, Aversa, Ilenia, Gallo, Raffaella, Giordano, Caterina, Serapide, Francesca, Fusco, Paolo, Viglietto, Giuseppe, Cuda, Giovanni, Costanzo, Francesco, Russo, Alessandro, Trecarichi, Enrico Maria, Torti, Carlo, and Palmieri, Camillo
- Subjects
- *
VACCINATION status , *VACCINE effectiveness , *MONONUCLEAR leukocytes , *VACCINATION , *SARS-CoV-2 - Abstract
Background: The evolving variants of SARS-CoV-2 may escape immunity from prior infections or vaccinations. It's vital to understand how immunity adapts to these changes. Both infection and mRNA vaccination induce T cells that target the Spike protein. These T cells can recognize multiple variants, such as Delta and Omicron, even if neutralizing antibodies are weakened. However, the degree of recognition can vary among people, affecting vaccine efficacy. Previous studies demonstrated the capability of T-cell receptor (TCR) repertoire analysis to identify conserved and immunodominant peptides with cross-reactive potential among variant of concerns. However, there is a need to extend the analysis of the TCR repertoire to different clinical scenarios. The aim of this study was to examine the Spike-specific TCR repertoire profiles in natural infections and those with combined natural and vaccine immunity. Methods: A T-cell enrichment approach and bioinformatic tools were used to investigate the Spike-specific TCRβ repertoire in peripheral blood mononuclear cells of previously vaccinated (n = 8) or unvaccinated (n = 6) COVID-19 patients. Results: Diversity and clonality of the TCRβ repertoire showed no significant differences between vaccinated and unvaccinated groups. When comparing the TCRβ data to public databases, 692 unique TCRβ sequences linked to S epitopes were found in the vaccinated group and 670 in the unvaccinated group. TCRβ clonotypes related to spike regions S135-177, S264-276, S319-350, and S448-472 appear notably more prevalent in the vaccinated group. In contrast, the S673-699 epitope, believed to have super antigenic properties, is observed more frequently in the unvaccinated group. In-silico analyses suggest that mutations in epitopes, relative to the main SARS-CoV-2 variants of concern, don't hinder their cross-reactive recognition by associated TCRβ clonotypes. Conclusions: Our findings reveal distinct TCRβ signatures in vaccinated and unvaccinated individuals with COVID-19. These differences might be associated with disease severity and could influence clinical outcomes. Trial registration: FESR/FSE 2014–2020 DDRC n. 585, Action 10.5.12, noCOVID19@UMG. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. An autochthonous case of cutaneous bacillary angiomatosis not related to major immunosuppression: An emerging or overlooked disease?
- Author
-
Rotundo, Salvatore, Bono, Francesco, Mazzitelli, Maria, Scaglione, Vincenzo, Lamberti, Angelo Giuseppe, Giancotti, Aida, Tucci, Luigi, Costa, Chiara, Tassone, Maria Teresa, Morrone, Helen Linda, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
BARTONELLA henselae , *HIV-positive persons , *IMMUNOSUPPRESSION , *IMMUNOCOMPROMISED patients , *PHYSICIANS - Abstract
• Consider cutaneous bacillary angiomatosis in mildly immunocompromised patients. • There are uncertainties about the best antibiotic treatment and its duration. • Validation and use of molecular methods can improve diagnosis and therapy outcomes. Cutaneous bacillary angiomatosis (cBA) is a vascular proliferative disorder due to Bartonella henselae or Bartonella quintana that has been mostly described in people living with HIV. Since cBA is considered to be rare in hosts not affected by major immunosuppression, it could be underdiagnosed in this population. Moreover, antimicrobial treatment of cBA has been poorly validated, thus reporting experiences on this clinical entity is important. We reported a challenging and well-characterized case of an Italian 67-year-old gentleman without a history of major immunocompromizing conditions, although he was affected by conditions that can be associated with impaired immune function. The patient reported herein was diagnosed after a long time since the initiation of symptoms and was successfully treated with combined antibiotic therapy including macrolides and quinolones under the guidance of molecular test results. Physicians should consider cBA as a possible manifestation of Bartonella spp. Infection in patients not suffering from major immunocompromizing conditions. Until evidence-based guidelines are available, molecular tests together with severity and extension of the disease can be useful to personalize the type of treatment and its duration. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies.
- Author
-
Rotundo, Salvatore, Borelli, Massimo, Scaglione, Vincenzo, Lionello, Rosaria, Biamonte, Flavia, Olivadese, Vincenzo, Quirino, Angela, Morrone, Helen Linda, Matera, Giovanni, Costanzo, Francesco Saverio, Russo, Alessandro, Trecarichi, Enrico Maria, Torti, Carlo, IDTM UMG COVID-19 Group, Serapide, Francesca, Tassone, Bruno, Fusco, Paolo, Davoli, Chiara, La Gamba, Valentina, and Berardelli, Lavinia
- Subjects
- *
COVID-19 , *MONOCLONAL antibodies , *CONVENIENCE sampling (Statistics) , *ASYMPTOMATIC patients , *DISEASE progression - Abstract
In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-62/lymphocyte count ratio (IL-62/LC) was able to predict clinical worsening both in early stages of COVID-19 and in oxygen-requiring patients. Moreover, we analysed 18 most at-risk patients with asymptomatic or mild disease treated with both moAbs and antiviral treatment and found that only 2 had clinical progression, while patients with a similar risk were reported to have an unfavourable outcome in most cases from recent data. In only one of our 18 patients, clinical progression was attributable to COVID-19, and in the other cases, clinical progression was observed despite IL-62/LC being above the risk cut-off. In conclusion, IL-62/LC may be a valuable method to identify patients requiring more aggressive treatments both in earlier and later stages of the disease; however, most at-risk patients can be protected from clinical worsening by combining moAbs and antivirals, even if levels of the IL-62/LC biomarker are lower than the risk cut-off. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Touching Base with Some Mediterranean Diseases of Interest from Paradigmatic Cases at the "Magna Graecia" University Unit of Infectious Diseases: A Didascalic Review.
- Author
-
Lionello, Ferdinando Carmelo Pio, Rotundo, Salvatore, Bruno, Gabriele, Marino, Gabriella, Morrone, Helen Linda, Fusco, Paolo, Costa, Chiara, Russo, Alessandro, Trecarichi, Enrico Maria, Beltrame, Anna, and Torti, Carlo
- Subjects
- *
COMMUNICABLE diseases , *THALASSEMIA , *Q fever , *ZOONOSES , *HIV-positive persons , *PRIMARY immunodeficiency diseases - Abstract
Among infectious diseases, zoonoses are increasing in importance worldwide, especially in the Mediterranean region. We report herein some clinical cases from a third-level hospital in Calabria region (Southern Italy) and provide a narrative review of the most relevant features of these diseases from epidemiological and clinical perspectives. Further, the pathogenic mechanisms involved in zoonotic diseases are reviewed, focusing on the mechanisms used by pathogens to elude the immune system of the host. These topics are of particular concern for individuals with primary or acquired immunodeficiency (e.g., people living with HIV, transplant recipients, patients taking immunosuppressive drugs). From the present review, it appears that diagnostic innovations and the availability of more accurate methods, together with better monitoring of the incidence and prevalence of these infections, are urgently needed to improve interventions for better preparedness and response. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Immunity to Human Immunodeficiency Virus (HIV) Infection.
- Author
-
Torti, Carlo, Paiardini, Mirko, and Gori, Andrea
- Subjects
- *
HIV , *HIGHLY active antiretroviral therapy , *IMMUNITY - Abstract
An introduction is presented in which the editors discuss various reports within the issue on topics including HIV, highly active antiretroviral therapy (HAART) and immunity.
- Published
- 2012
- Full Text
- View/download PDF
30. No Evidence of Relation Between Peripheral Neuropathy and Presence of Hemochromatosis Gene Mutations in HIV-1 — Positive Patients.
- Author
-
Costarelli, Silvia, Torti, Carlo, Benerini Gatta, Luisa, Tinelli, Carmine, Lapadula, Giuseppe, Quiros-Roldan, Eugenia, Izzo, Haria, Castelnuovo, Filippo, Biasiotto, Giorgio, Arosio, Paolo, and Carosi, Giampiero
- Subjects
- *
LETTERS to the editor , *HIV infections - Abstract
A letter to the editor is presented in response to an article about the relation between peripheral neuropathy and the presence of hemochromatosis gene mutations in HIV-1-positive patients.
- Published
- 2007
- Full Text
- View/download PDF
31. Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study.
- Author
-
Ingle, Suzanne M, Miro, Jose M, May, Margaret T, Cain, Lauren E, Schwimmer, Christine, Zangerle, Robert, Sambatakou, Helen, Cazanave, Charles, Reiss, Peter, Brandes, Vanessa, Bucher, Heiner C, Sabin, Caroline, Vidal, Francesc, Obel, Niels, Mocroft, Amanda, Wittkop, Linda, Monforte, Antonella d'Arminio, Torti, Carlo, Mussini, Cristina, and Furrer, Hansjakob
- Subjects
- *
HIV infections , *HIV-positive persons , *STRUCTURAL equation modeling , *CONFIDENCE intervals , *TIME , *MORTALITY , *VIRAL load , *ANTIRETROVIRAL agents , *HEALTH outcome assessment , *CRYPTOCOCCUS neoformans , *CD4 lymphocyte count , *DESCRIPTIVE statistics , *RESEARCH funding , *MENINGITIS , *EARLY medical intervention , *LONGITUDINAL method , *HIV ,DEVELOPED countries - Abstract
Background Randomized controlled trials (RCTs) from low- and middle-income settings suggested that early initiation of antiretroviral therapy (ART) leads to higher mortality rates among people with HIV (PWH) who present with cryptococcal meningitis (CM). There is limited information about the impact of ART timing on mortality rates in similar people in high-income settings. Methods Data on ART-naive PWH with CM diagnosed from 1994 to 2012 from Europe/North America were pooled from the COHERE, NA-ACCORD, and CNICS HIV cohort collaborations. Follow-up was considered to span from the date of CM diagnosis to earliest of the following: death, last follow-up, or 6 months. We used marginal structural models to mimic an RCT comparing the effects of early (within 14 days of CM) and late (14–56 days after CM) ART on all-cause mortality, adjusting for potential confounders. Results Of 190 participants identified, 33 (17%) died within 6 months. At CM diagnosis, their median age (interquartile range) was 38 (33–44) years; the median CD4+ T-cell count, 19/μL (10–56/μL); and median HIV viral load, 5.3 (4.9–5.6) log10 copies/mL. Most participants (n = 157 [83%]) were male, and 145 (76%) started ART. Mimicking an RCT, with 190 people in each group, there were 13 deaths among participants with an early ART regimen and 20 deaths among those with a late ART regimen. The crude and adjusted hazard ratios comparing late with early ART were 1.28 (95% confidence interval,.64–2.56) and 1.40 (.66–2.95), respectively. Conclusions We found little evidence that early ART was associated with higher mortality rates among PWH presenting with CM in high-income settings, although confidence intervals were wide. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. SARS CoV-2 spike protein-guided exosome isolation facilitates detection of potential miRNA biomarkers in COVID-19 infections.
- Author
-
Mimmi, Selena, Zimbo, Anna Maria, Rotundo, Salvatore, Cione, Erika, Nisticò, Nancy, Aloisio, Annamaria, Maisano, Domenico, Tolomeo, Anna Maria, Dattilo, Vincenzo, Lionello, Rosaria, Fioravanti, Antonella, Di Loria, Antonio, Quirino, Angela, Marascio, Nadia, Russo, Alessandro, Trecarichi, Enrico Maria, Matera, Giovanni, Quinto, Ileana, Torti, Carlo, and Iaccino, Enrico
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *CORONAVIRUS spike protein , *EXOSOMES , *COVID-19 pandemic - Abstract
Nearly three years into the pandemic, SARS-CoV-2 infections are occurring in vaccinated and naturally infected populations. While humoral and cellular responses in COVID-19 are being characterized, novel immune biomarkers also being identified. Recently, an increase in angiotensin-converting enzyme 2 expressing (aka, ACE2 positive) circulating exosomes (ExoACE2) were identified in the plasma of COVID-19 patients (El-Shennawy et al.). In this pilot study, we describe a method to characterize the exosome-associated microRNA (exo-miRNA) signature in ACE2-positive and ACE2-negative exosomal populations (non-ExoACE2). We performed a sorting protocol using the recombinant biotin-conjugated SARS CoV-2 spike protein containing the receptor binding domain (RBD) on plasma samples from six patients. Following purification, exo-miRNA were characterized for ACE2-positive and ACE2-negative exosome subpopulations by RT-PCR. We identified differential expression of several miRNA. Specifically let-7g-5p and hsa-miR-4454+miR-7975 were upregulated, while hsa-miR-208a-3p and has-miR-323-3p were downregulated in ExoACE2 vs. non-ExoACE2. The SARS CoV-2 spike-protein guided exosome isolation permits isolation of ExoACE2 exosomes. Such purification facilitates detailed characterization of potential biomarkers (e.g. exo-miRNA) for COVID-19 patients. This method could be used for future studies to further the understanding mechanisms of host response against SARS CoV-2. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. A Rare Complication of Ascariasis: A Case of Acute Interstitial Nephritis.
- Author
-
Carullo, Nazareno, Divenuto, Francesca, Marascio, Nadia, Adams, Neill James, Giancotti, Aida, Comi, Nicolino, Faga, Teresa, Bolignano, Davide, Coppolino, Giuseppe, Serapide, Francesca, Costa, Chiara, Torti, Carlo, Matera, Giovanni, Quirino, Angela, and Andreucci, Michele
- Subjects
- *
INTERSTITIAL nephritis , *ACUTE kidney failure , *BLOOD cell count , *KIDNEY failure , *ASCARIS lumbricoides , *KIDNEY physiology - Abstract
Acute interstitial nephritis (AIN) due to helminths is a rare cause of acute kidney injury (AKI). Helminthiases often progresses insidiously, making diagnosis difficult. This was the case of a 72-year-old man, who presented with renal failure, itching and diarrhoea. Urinalysis revealed leukocyturia, microhaematuria and mild proteinuria. A full blood count revealed leucocytosis with eosinophilia. A stool parasitological examination revealed fertilised eggs of Ascaris lumbricoides. Tubulointerstitial nephropathy secondary to A. lumbricoides infection was suspected. A percutaneous renal biopsy was not performed since the patient refused the anti-platelet therapy discontinuation. Mebendazole, albendazole and prednisone therapy was administered. After worm eradiation and discharge, recovery from the parasitosis, absence of pruritus and eosinophilia, and progressive improvement of renal function were observed, strongly suggesting a causal relationship between Ascaris infection and AIN. Parasite infection should be considered in the differential diagnosis of unexplained renal failure because early diagnosis and treatment are necessary to avoid irreversible complications. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Lights and Shadows of Sepsis Management: Challenges and Future Perspectives.
- Author
-
Russo, Alessandro, Pallone, Rita, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
SEPSIS , *NEONATAL sepsis , *SCIENTIFIC knowledge , *STAPHYLOCOCCAL diseases - Abstract
Prompt empirical broad-spectrum antibiotic therapy and source control of infection are the most effective treatment strategies in sepsis. As reported above, the dysregulated host response to infection, leading to sepsis and septic shock, is a life-threatening event that is associated with high mortality rate, despite advances in organ support and antimicrobial therapy. Moreover, as sepsis and septic shock are characterized by a dysfunction of the immune response, adjunctive immune-modulatory treatments have been developed in support of antibiotic therapies to restore immune response. The complex interaction between microorganisms, the host's immune response, and the release of pro- and anti-inflammatory factors influence the evolution of sepsis. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
35. The Role of Gut Microbiota in the Clinical Outcome of Septic Patients: State of the Art and Future Perspectives.
- Author
-
Marascio, Nadia, Scarlata, Giuseppe Guido Maria, Romeo, Francesco, Cicino, Claudia, Trecarichi, Enrico Maria, Quirino, Angela, Torti, Carlo, Matera, Giovanni, and Russo, Alessandro
- Subjects
- *
GUT microbiome , *HIGH-income countries , *SEPSIS , *PILOT projects , *RESEARCH teams - Abstract
Sepsis is a life-threatening multiple-organ dysfunction caused by a dysregulated host response to infection, with high mortality worldwide; 11 million deaths per year are attributable to sepsis in high-income countries. Several research groups have reported that septic patients display a dysbiotic gut microbiota, often related to high mortality. Based on current knowledge, in this narrative review, we revised original articles, clinical trials, and pilot studies to evaluate the beneficial effect of gut microbiota manipulation in clinical practice, starting from an early diagnosis of sepsis and an in-depth analysis of gut microbiota. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Update on different aspects of HCV variability: focus on NS5B polymerase.
- Author
-
Marascio, Nadia, Torti, Carlo, Liberto, Maria, and Focà, Alfredo
- Abstract
The study of hepatitis C virus (HCV) genotypes/subtypes, quasispecies and recombinants obtained by virus genome sequencing are important for epidemiological studies, to trace the source of infection, for development of new direct acting antivirals (DAAs) therapy and for understanding antiviral selection pressures. The HCV NS5B gene encodes a polymerase, which is responsible for virus replication and is a potential target for the development of antiviral agents. Many studies for classification of HCV use a particular segment of the NS5B gene, in addition to other specific regions, and phylogenetic analysis. Actually, some nucleoside/nucleotide analogues and non-nucleoside inhibitors target NS5B protein. This review focuses on HCV variability, phylogenetic analysis and the role of NS5B in the virus-host interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
37. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
- Author
-
Fusco, Paolo, Nasta, Paola, Quiros-Roldan, Eugenia, Tondinelli, Alice, Costa, Cecilia, Fornabaio, Chiara, Mazzini, Nicola, Prosperi, Mattia, Torti, Carlo, and Carosi, Giampiero
- Subjects
- *
RALTEGRAVIR , *RITONAVIR , *ANTIRETROVIRAL agents , *LONGITUDINAL method , *HIV infection transmission , *VIRAL hepatitis , *HIV-positive persons - Abstract
Background: Dolutegravir (DTG) is recommended by international guidelines as a main component of an optimal initial regimen of cART (combination antiretroviral treatment) in people living with HIV (PLWH) and in case of switching for failure or optimization strategies. However, studies on the performance of DTG-containing regimens and indications for switching therapies in the long term are sparse. The purpose of this study was to evaluate prospectively the performance of DTG-based regimens, using the metrics of "efficacy", "safety", "convenience" and ''durability", among a nationally representative cohort of PLWH in Italy. Methods: We selected all PLWH in four centers of the MaSTER cohort who initiated a DTG-based regimen either when naïve or following a regimen switch between 11 July 2018 and 2 July 2021. Participants were followed until the outcomes were recorded or until the end of the study on 4 August 2022, whichever occurred first. Interruption was reported even when a participant switched to another DTG-containing regimen. Survival regression models were fitted to evaluate associations between therapy performance and age, sex, nationality, risk of HIV transmission, HIV RNA suppression status, CD4+ T-cell count, year of HIV diagnosis, cART status (naïve or experienced), cART backbone and viral hepatitis coinfection. Results: There were 371 participants in our cohort who initiated a DTG-based cART regimen in the time frame of the study. The population was predominantly male (75.2%), of Italian nationality (83.3%), with a history of cART use (80.9%), and the majority initiated a DTG-based regimen following a switch strategy in 2019 (80.1%). Median age was 53 years (interquartile range (IQR): 45–58). Prior cART regimen was based mostly on a combination of NRTI drugs plus a PI-boosted drug (34.2%), followed by a combination of NRTIs plus an NNRTI (23.5%). Concerning the NRTI backbone, the majority comprised 3TC plus ABC (34.5%), followed by 3TC alone (28.6%). The most reported transmission risk factor was heterosexual intercourse (44.2%). Total interruptions of the first DTG-based regimen were registered in 58 (15.6%) participants. The most frequent reason for interruption was due to cART simplification strategies, which accounted for 52%. Only 1 death was reported during the study period. The median time of total follow-up was 556 days (IQR: 316.5–722.5). Risk factors for poor performance of DTG-containing-regimens were found to be: a backbone regimen containing tenofovir, being cART naïve, having detectable HIV RNA at baseline, FIB-4 score above 3.25 and having a cancer diagnosis. By contrast, protective factors were found to be: higher CD4+ T-cell counts and higher CD4/CD8 ratio at baseline. Conclusion: DTG-based regimens were used mainly as a switching therapy in our cohort of PLWH who had undetectable HIV RNA and a good immune status. In this type of population, the durability of DTG-based regimens was maintained in 84.4% of participants with a modest incidence of interruptions mostly due to cART simplification strategies. The results of this prospective real-life study confirm the apparent low risk of changing DTG-containing regimens due to virological failure. They may also help physicians to identify people with increased risk of interruption for different reasons, suggesting targeted medical interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: An exploratory study.
- Author
-
Garofalo, Eugenio, Biamonte, Flavia, Palmieri, Camillo, Battaglia, Anna Martina, Sacco, Alessandro, Biamonte, Eugenio, Neri, Giuseppe, Antico, Giulio Cesare, Mancuso, Serafina, Foti, Giuseppe, Torti, Carlo, Costanzo, Francesco Saverio, Longhini, Federico, and Bruni, Andrea
- Subjects
- *
COVID-19 , *SARS-CoV-2 , *BREAKTHROUGH infections , *CHEMILUMINESCENCE immunoassay , *VACCINATION , *IMMUNOGLOBULIN M , *IMMUNOGLOBULINS - Abstract
Background: Despite an apparent effective vaccination, some patients are admitted to the hospital after SARS-CoV-2 infection. The role of adaptive immunity in COVID-19 is growing; nonetheless, differences in the spike-specific immune responses between patients requiring or not hospitalization for SARS-CoV-2 infection remains to be evaluated. In this study, we aim to evaluate the spike-specific immune response in patients with mild-moderate or severeSARS-CoV-2 infection, after breakthrough infection following two doses of BNT162b2 mRNA vaccine. Methods: We included three cohorts of 15 cases which received the two BNT162b2 vaccine doses in previous 4 to 7 months: 1) patients with severe COVID-19; 2) patients with mild-moderate COVID-19 and 3) vaccinated individuals with a negative SARS-CoV-2 molecular pharyngeal swab (healthy subjects). Anti-S1 and anti-S2 specific SARS-CoV-2 IgM and IgG titers were measured through a chemiluminescence immunoassay technology. In addition, the frequencies of IFNγ-releasing cells were measured by ELISpot. Results: The spike-specific IFNγ-releasing cells were significantly lower in severe patients (8 [0; 26] s.f.c.×106), as compared to mild-moderate patients (135 [64; 159] s.f.c.×106; p<0.001) and healthy subjects (103 [50; 188] s.f.c.×106; p<0.001). The anti-Spike protein IgG levels were similar among the three cohorts of cases (p = 0.098). All cases had an IgM titer below the analytic sensitivity of the test. The Receiver Operating Curve analysis indicated the rate of spike-specific IFNγ-releasing cells can discriminate correctly severe COVID-19 and mild-moderate patients (AUC: 0.9289; 95%CI: 0.8376–1.000; p< 0.0001), with a diagnostic specificity of 100% for s.f.c. > 81.2 x 106. Conclusions: 2-doses vaccinated patients requiring hospitalization for severe COVID-19 show a cellular-mediated immune response lower than mild-moderate or healthy subjects, despite similar antibody titers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
39. The Spread of SARS-CoV-2 Omicron Variant in CALABRIA: A Spatio-Temporal Report of Viral Genome Evolution.
- Author
-
Veneziano, Claudia, Marascio, Nadia, De Marco, Carmela, Quaresima, Barbara, Biamonte, Flavia, Trecarichi, Enrico Maria, Santamaria, Gianluca, Quirino, Angela, Torella, Daniele, Quattrone, Aldo, Matera, Giovanni, Torti, Carlo, De Filippo, Caterina, Costanzo, Francesco Saverio, and Viglietto, Giuseppe
- Subjects
- *
SARS-CoV-2 Omicron variant , *WHOLE genome sequencing , *SARS-CoV-2 - Abstract
We investigated the evolution of SARS-CoV-2 spread in Calabria, Southern Italy, in 2022. A total of 272 RNA isolates from nasopharyngeal swabs of individuals infected with SARS-CoV-2 were sequenced by whole genome sequencing (N = 172) and/or Sanger sequencing (N = 100). Analysis of diffusion of Omicron variants in Calabria revealed the prevalence of 10 different sub-lineages (recombinant BA.1/BA.2, BA.1, BA.1.1, BA.2, BA.2.9, BA.2.10, BA.2.12.1, BA.4, BA.5, BE.1). We observed that Omicron spread in Calabria presented a similar trend as in Italy, with some notable exceptions: BA.1 disappeared in April in Calabria but not in the rest of Italy; recombinant BA.1/BA.2 showed higher frequency in Calabria (13%) than in the rest of Italy (0.02%); BA.2.9, BA.4 and BA.5 emerged in Calabria later than in other Italian regions. In addition, Calabria Omicron presented 16 non-canonical mutations in the S protein and 151 non-canonical mutations in non-structural proteins. Most non-canonical mutations in the S protein occurred mainly in BA.5 whereas non-canonical mutations in non-structural or accessory proteins (ORF1ab, ORF3a, ORF8 and N) were identified in BA.2 and BA.5 sub-lineages. In conclusion, the data reported here underscore the importance of monitoring the entire SARS-CoV-2 genome. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience.
- Author
-
Quirino, Angela, Cicino, Claudia, Scaglione, Vincenzo, Marascio, Nadia, Serapide, Francesca, Scarlata, Giuseppe Guido Maria, Lionello, Rosaria, Divenuto, Francesca, La Gamba, Valentina, Pavia, Grazia, Russo, Alessandro, Torti, Carlo, Matera, Giovanni, and Trecarichi, Enrico Maria
- Subjects
- *
CARBAPENEM-resistant bacteria , *ACINETOBACTER baumannii , *KLEBSIELLA pneumoniae , *MULTIDRUG resistance in bacteria , *MICROBIAL sensitivity tests , *MEDICAL microbiology , *STENOTROPHOMONAS maltophilia - Published
- 2023
- Full Text
- View/download PDF
41. Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2.
- Author
-
Rotundo, Salvatore, Vecchio, Eleonora, Abatino, Antonio, Giordano, Caterina, Mancuso, Serafina, Tassone, Maria Teresa, Costa, Chiara, Russo, Alessandro, Trecarichi, Enrico Maria, Cuda, Giovanni, Costanzo, Francesco Saverio, Palmieri, Camillo, and Torti, Carlo
- Subjects
- *
COVID-19 , *MONOCLONAL antibodies , *BREAKTHROUGH infections , *T cells , *TREATMENT effectiveness , *VERBAL memory - Abstract
• Monoclonal antibody treatment does not hinder the short-term spike-specific cellular memory. • Vaccine breakthrough infection is associated with increased activated CD8+ cells. • Sotrovimab may hamper the T-cell memory in unvaccinated patients. Neutralizing monoclonal antibodies (moAbs) improves clinical outcomes in patients with COVID-19 when administered during the initial days of infection. The action of moAbs may impair the generation or maintenance of effective immune memory, similar to that demonstrated in other viral diseases. We aimed to evaluate short-term memory T-cell responses in patients effectively treated with bamlanivimab/etesevimab, casirivimab/imdevimab, or sotrovimab (SOT). Spike (S)-specific T-cell responses were analyzed in 23 patients with COVID-19 (vaccinated or unvaccinated) before and after a median of 50 (range: 28-93) days from moAb treatment, compared with 11 vaccinated healthy controls. T-cell responses were measured by interferon-γ-enzyme-linked immunospot and flow cytometric activation-induced marker assay. No statistically significant difference in S-specific T-cell responses was observed between patients treated with moAb and vaccinated healthy controls. Bamlanivimab/etesevimab and casirivimab/imdevimab groups showed significant increases in cellular responses in paired baseline/postrecovery series, as well as vaccinated patients receiving SOT. In contrast, unvaccinated patients prescribed SOT presented no statistically significant increases in T-cell-responses, suggesting diverse impacts of different moAbs on the evolution of S-specific T-cell responses in vaccinated and unvaccinated patients. The moAbs did not hinder short-term memory S-specific T-cell responses in the overall group of patients; however, differences among moAbs must be further investigated both in vaccinated and unvaccinated individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Natural history of chronic hepatitis B in co-infected patients
- Author
-
Puoti, Massimo, Torti, Carlo, Bruno, Raffaele, Filice, Gaetano, and Carosi, Giampiero
- Subjects
- *
HEPATITIS B virus , *HIV-positive persons , *COMMUNICABLE diseases , *IMMUNE response - Abstract
HIV co-infection influences the course and natural history of hepatitis B virus (HBV) infection by impairing the quantity and quality of the innate and adaptive immune response. The rates of spontaneous resolution after acute infection and spontaneous anti-HBe and anti-HBs seroconversions are decreased, and levels of HBV replication are increased in HIV-infected patients. A more rapid progression of liver fibrosis and a higher rate of cirrhosis decompensation (but not hepatocellular carcinoma) have been demonstrated in co-infected patients. The risk of HBV-associated end-stage liver disease and liver-related mortality may be increased by HIV co-infection. Antiretroviral therapy may trigger spontaneous anti-HBe and anti-HBs seroconversion and/or a better immune control of HBV replication by restoring adaptive immunity, but can also increase hepatitis flares. Reactivation of chronic hepatitis B has been observed after suspension of anti-retrovirals with anti-HBV activity or after occurrence of HBV resistance to lamivudine. Future research should focus on: the impact of HIV-induced changes in innate and adaptive immune response and modifications induced by anti-retroviral therapy that may impact on progression of advanced chronic hepatitis B; the association between HBV genotype and clinical course of disease; and the role of occult HBV infection as a co-factor with other causes of liver injury. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
43. The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview.
- Author
-
Marascio, Nadia, De Caro, Carmen, Quirino, Angela, Mazzitelli, Maria, Russo, Emilio, Torti, Carlo, and Matera, Giovanni
- Subjects
- *
GUT microbiome , *HEPATITIS C virus , *COVID-19 pandemic , *MEDICAL care , *GENETIC variation - Abstract
Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut–liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut–liver axis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota.
- Author
-
Russo, Alessandro, Serapide, Francesca, Quirino, Angela, Tarsitano, Maria Grazia, Marascio, Nadia, Serraino, Riccardo, Rotundo, Salvatore, Matera, Giovanni, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
GUT microbiome , *SARS-CoV-2 , *MICROBIOLOGICAL techniques , *COVID-19 , *VIRAL transmission - Abstract
Early recognition and prompt management are crucial for improving survival in COVID-19 patients, and after 2 years of the pandemic, many efforts have been made to obtain an early diagnosis. A key factor is the use of fast microbiological techniques, considering also that COVID-19 patients may show no peculiar signs and symptoms that may differentiate COVID-19 from other infective or non-infective diseases. These techniques were developed to promptly identify SARS-CoV-2 infection and to prevent viral spread and transmission. However, recent data about clinical, radiological and laboratory features of COVID-19 at time of hospitalization could help physicians in early suspicion of SARS-CoV-2 infection and distinguishing it from other etiologies. The knowledge of clinical features and microbiological techniques will be crucial in the next years when the endemic circulation of SARS-CoV-2 will be probably associated with clusters of infection. In this review we provide a state of the art about new advances in microbiological and clinical findings of SARS-CoV-2 infection in hospitalized patients with a focus on pulmonary and extrapulmonary characteristics, including the role of gut microbiota. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience.
- Author
-
Russo, Alessandro, Gullì, Sara Palma, D'Avino, Alessandro, Borrazzo, Cristian, Carannante, Novella, Dezza, Francesco Cogliati, Covino, Sara, Polistina, Giorgio, Fiorentino, Giuseppe, Trecarichi, Enrico Maria, Mastroianni, Claudio Maria, Torti, Carlo, and Oliva, Alessandra
- Subjects
- *
CARBAPENEM-resistant bacteria , *ACINETOBACTER baumannii , *CATHETER-related infections , *FOSFOMYCIN , *PROPENSITY score matching , *COLONIZATION (Ecology) - Abstract
• Severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been reported increasingly. • Many in-vivo and in-vitro studies suggest a possible role of intravenous fosfomycin for the treatment of CRAB infections. • Cefiderocol-containing regimens were independently associated with survival and clinical success, whilst colistin-based regimens were associated with death and clinical failure. • The study data showed clinical features and use of different antibiotic regimens with a possible role for fosfomycin in combination for treatment of severe infections caused by CRAB. Severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been reported increasingly over the past few years. Many in-vivo and in-vitro studies have suggested a possible role of intravenous fosfomycin for the treatment of CRAB infections. This multi-centre, retrospective study included patients treated with intravenous fosfomycin for severe infections caused by CRAB admitted consecutively to four hospitals in Italy from December 2017 to December 2022. The primary goal of the study was to evaluate the risk factors associated with 30-day mortality in the study population. A propensity score matched analysis was added to the model. One hundred and two patients with severe infections caused by CRAB treated with an intravenous fosfomycin-containing regimen were enrolled in this study. Ventilator-associated pneumonia (VAP) was diagnosed in 59% of patients, primary bacteraemia in 22% of patients, and central-venous-catheter-related infection in 16% of patients. All patients were treated with a regimen containing intravenous fosfomycin, mainly in combination with cefiderocol (n =54), colistin (n =48) or ampicillin/sulbactam (n =18). Forty-eight (47%) patients died within 30 days. Fifty-eight (57%) patients experienced clinical therapeutic failure. Cox regression analysis showed that diabetes, primary bacteraemia and a colistin-containing regimen were independently associated with 30-day mortality, whereas adequate source control of infection, early 24-h active in-vitro therapy, and a cefiderocol-containing regimen were associated with survival. A colistin-based regimen, A. baumannii colonization and primary bacteraemia were independently associated with clinical failure. Conversely, adequate source control of infection, a cefiderocol-containing regimen, and early 24-h active in-vitro therapy were associated with clinical success. Different antibiotic regimens containing fosfomycin in combination can be used for treatment of severe infections caused by CRAB. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets.
- Author
-
Russo, Alessandro, Morrone, Helen Linda, Rotundo, Salvatore, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
PULMONARY aspergillosis , *INFLUENZA , *COVID-19 pandemic , *COVID-19 , *VIRUS diseases , *DRUG target , *IMMUNOSUPPRESSION - Abstract
During the SARS-CoV-2 pandemic, a higher incidence of invasive pulmonary aspergillosis was observed in patients affected by Coronavirus disease 2019 (COVID-19), leading to the delineation of a new entity named COVID-19 associated pulmonary aspergillosis (CAPA). A predisposition to invasive infection caused by Aspergillus spp. in SARS-CoV-2 infected patients can be ascribed either to the direct viral-mediated damage of the respiratory epithelium, as already observed in influenza H1N1 virus infections, or to the dysregulated immunity associated with COVID-19. This narrative review focuses on the impact of immune impairment, particularly due to cytokine dysregulation caused by Aspergillus spp. superinfection in COVID-19 for a more in-depth understanding of the molecular pathways implicated in CAPA. As immune competence has proven to be essential in protecting against CAPA onset, a role already threatened by SARS-CoV-2 infection itself, preventive strategies should focus on reducing factors that could further target the host immune system. We also aimed to focus on well-known and less-known risk factors for IPA in COVID-19 patients, related to the main causes of immune suppression, both virus-mediated and iatrogenic, including treatments currently indicated for COVID-19. Lastly, possible preventive strategies aimed at reducing morbidity and mortality due to CAPA could be implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Bacterial Ventilator-Associated Pneumonia in COVID-19 Patients: Data from the Second and Third Waves of the Pandemic.
- Author
-
Russo, Alessandro, Olivadese, Vincenzo, Trecarichi, Enrico Maria, and Torti, Carlo
- Subjects
- *
VENTILATOR-associated pneumonia , *COVID-19 , *INTENSIVE care units , *CORONAVIRUS diseases , *ETIOLOGY of diseases , *RESPIRATORY insufficiency - Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, many patients requiring invasive mechanical ventilation were admitted to intensive care units (ICU) for COVID-19-related severe respiratory failure. As a matter of fact, ICU admission and invasive ventilation increased the risk of ventilator-associated pneumonia (VAP), which is associated with high mortality rate and a considerable burden on length of ICU stay and healthcare costs. The objective of this review was to evaluate data about VAP in COVID-19 patients admitted to ICU that developed VAP, including their etiology (limiting to bacteria), clinical characteristics, and outcomes. The analysis was limited to the most recent waves of the epidemic. The main conclusions of this review are the following: (i) P. aeruginosa, Enterobacterales, and S. aureus are more frequently involved as etiology of VAP; (ii) obesity is an important risk factor for the development of VAP; and (iii) data are still scarce and increasing efforts should be put in place to optimize the clinical management and preventative strategies for this complex and life-threatening disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience.
- Author
-
Quirino, Angela, Scaglione, Vincenzo, Marascio, Nadia, Mazzitelli, Maria, Garofalo, Eugenio, Divenuto, Francesca, Serapide, Francesca, Bruni, Andrea, Lionello, Rosaria, Pavia, Grazia, Costa, Chiara, Giancotti, Aida, Peronace, Cinzia, Longhini, Federico, Russo, Alessandro, Liberto, Maria Carla, Matera, Giovanni, Torti, Carlo, and Trecarichi, Enrico Maria
- Subjects
- *
MAGNETIC resonance , *DEATH rate , *INFECTION , *COMPARATOR circuits - Abstract
Background: T2Dx was approved by the US Food and Drug Administration for the rapid detection of a modified panel of ESKAPE bacterial species or Candida spp. causing bloodstream infection (BSI).Patients and Methods: We performed a retrospective, observational study from January 1, 2018 to December 31, 2019 of all hospitalised patients with suspected BSI who underwent assessment using T2Dx in addition to standard blood culture (BC). T2-positive patients (cases) were compared to a matched group of patients with BSI documented only by BC (1:2 ratio) to investigate the possible impact of T2Dx on the appropriateness of empirical antimicrobial therapy and 21-day mortality.Results: In total, 78 T2Dx-analysed samples (49 patients) were analysed. The T2Dx assay result was positive for18 patients and negative for 31 patients. The concordance rates of the T2Bacteria Panel and T2Candida Panel results with those of standard BC were 74.4% and 91.4%, respectively. In the matched analysis, inappropriate empiric antimicrobial therapy administration was significantly less frequent in cases than in comparators (5.5% vs. 38.8%). The 21-day mortality rate was twofold lower in cases than in comparators (22.2% vs. 44.4%), although the difference was not significant. No other analysed variables were significantly different between the two groups.Conclusions: This study illustrated that T2Dx might be associated with an increase in the appropriateness of empiric antimicrobial therapy in patients with BSI. Further studies are needed to evaluate whether the T2Dx assay can improve patient outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
49. Molecular characterization of Schistosoma infections in African migrants: identification of a Schistosoma haematobium-bovis hybrid in bladder biopsies.
- Author
-
Marascio, Nadia, Loria, Maria Teresa, Lamberti, Angelo Giuseppe, Pavia, Grazia, Adams, Neill James, Quirino, Angela, Divenuto, Francesca, Mazzitelli, Maria, Greco, Giuseppe, Trecarichi, Enrico Maria, Perandin, Francesca, Bisoffi, Zeno, Webster, Bonnie L, Liberto, Maria Carla, Torti, Carlo, and Matera, Giovanni
- Subjects
- *
SCHISTOSOMIASIS diagnosis , *AFRICANS , *NOMADS , *BLADDER , *TREMATODA , *BIOPSY , *ANIMALS - Abstract
The I S. haematobium cox1 i data from all samples matched the common H1 haplotypes found across mainland Africa.[7] The I cox1 i data from the bladder biopsy identified both I S. bovis i and I S. haematobium i mitochondrial DNA. Keywords: ITS2; cox1; Schistosoma hybrid; phylogenetic analysis EN ITS2 cox1 Schistosoma hybrid phylogenetic analysis 1 3 3 11/09/22 20221001 NES 221001 Schistosomiasis is a neglected tropical disease affecting up to 90% of people living in Africa.[1] The emergence of natural inter I Schistosoma i species hybrids clearly highlights potential risks of mixing between human and animal infections, enhancing transmission and the spread of new strains.[2] In particular, I Schistosoma haematobium i and I Schistosoma bovis i are closely related, are known to hybridize and also share snail intermediate hosts of the genus I Bulinus i .[3] The I S. haematobium-bovis i hybrid diagnosis in patients plays an important role in explaining unusual morbidities and disease outcomes together with the potential risk of introduction into non-endemic areas I . i [2],[4] Herein, to identify the potential presence of I S. haematobium-bovis i hybrids, we molecularly characterized typical and atypical eggs, presumed to be I S. haematobium i , collected from young African migrants. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
50. Protura of Italy, with a key to species and their distribution.
- Author
-
Galli, Loris, Capurro, Matteo, and Torti, Carlo
- Subjects
- *
PROTURA , *GEOGRAPHICAL distribution of insects , *ENTOMOLOGY , *TAXONOMY - Abstract
The Italian Protura were studied basing on 5103 specimens from 198 sampling areas, along with bibliographic data from 49 collecting sites. 17 out of the 20 Italian regions are covered. As a result, 40 species have been identified (belonging to 8 genera and 4 families), 6 of which are new records for the Italian fauna. A key to the Italian species is reported, followed by a series of distribution maps and brief remarks for some of them. A preliminary biogeographical overview allowed us to delineate the chorological categories of these species, 10 of which are actually known only in Italy. The comparison with the species richness known for some best studied Central and Eastern European Countries leads us to speculate that widening our research, Italian Protura check-list will be much implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.